HYBIO(SZ:300199)2024-10-29 10:45Revenue and Profitability - Revenue for Q3 2024 reached ¥119,504,816.36, an increase of 56.67% compared to the same period last year[3] - Net profit attributable to shareholders was -¥24,446,846.64, a decrease of 83.30% year-on-year[3] - Total operating revenue for Q3 2024 was CNY 375.23 million, a decrease of 6.5% compared to CNY 401.56 million in Q3 2023[15] - Net profit for Q3 2024 was a loss of CNY 35.83 million, compared to a loss of CNY 181.77 million in the same period last year, indicating an improvement[17] - The company recorded a net loss attributable to shareholders of CNY 34.81 million, an improvement from a loss of CNY 180.55 million in Q3 2023[18] - Basic and diluted earnings per share were both -CNY 0.04, compared to -CNY 0.20 in the same quarter last year[18] Cash Flow and Financing - Net cash flow from operating activities for the year-to-date was ¥88,069,613.03, representing a significant increase of 262.17%[3] - Cash flow from financing activities increased by 146.98% to ¥1,241,333,185.23, primarily due to increased borrowings[8] - Total cash inflow from financing activities amounted to ¥1,241,333,185.23, up from ¥502,603,307.30 in the previous year, indicating a growth of approximately 147.5%[20] - Cash outflow from financing activities was ¥1,507,182,727.29, compared to ¥653,883,387.54 in the previous year, resulting in a net cash flow from financing activities of -¥265,849,542.06[20] - The company reported a net increase in cash and cash equivalents of -¥204,507,285.80, compared to -¥48,999,537.57 in the previous year[20] - Cash and cash equivalents at the end of the period stood at ¥135,428,940.64, a significant increase from ¥49,993,711.72 in the previous year[20] Expenses and Cost Management - The company reported a 57.40% reduction in selling expenses, totaling ¥70,260,228.90 for the first nine months of 2024[7] - Research and development expenses decreased by 49.77% to ¥59,329,000.15 year-to-date[7] - Total operating costs decreased significantly to CNY 459.58 million from CNY 635.02 million, reflecting a reduction of 27.6%[15] - Research and development expenses were CNY 59.33 million, down 50.3% from CNY 118.11 million in Q3 2023[17] - The company paid ¥107,780,020.47 in employee compensation, down from ¥128,095,004.90 in the previous year, reflecting a decrease of approximately 15.5%[20] - Tax payments decreased to ¥24,207,619.42 from ¥57,429,234.97, showing a reduction of approximately 57.8%[20] Assets and Liabilities - Total assets as of September 30, 2024, were ¥3,117,118,764.54, down 4.88% from the end of the previous year[3] - The company’s total equity attributable to shareholders decreased by 6.84% to ¥706,930,696.43 compared to the end of the previous year[3] - As of September 30, 2024, the total current assets amounted to CNY 548,032,020.70, a decrease of 19.8% from CNY 683,638,339.56 in the previous period[13] - The company’s accounts receivable decreased to CNY 98,885,945.45 from CNY 142,348,644.69, a decline of 30.5%[13] - The company’s total assets amounted to CNY 5,686,104,764.54 as of September 30, 2024[14] - The company reported a total liability of CNY 2.39 billion, a decrease from CNY 2.49 billion year-over-year[15] - The company’s total non-current assets were CNY 2,569,086,743.84, slightly down from CNY 2,593,555,372.00[14] Inventory and Supply Agreements - Inventory increased by 63.96% to ¥250,198,043.27, attributed to stockpiling for future sales[6] - The inventory increased significantly to CNY 250,198,043.27, up 63.9% from CNY 152,593,626.36[14] - The company signed a product supply agreement with DS3 RX LLC for approximately USD 8.1 million (about CNY 58.89 million) for GLP-1 raw materials[12] - The company received a drug registration certificate for its Asemaglutide injection from the National Medical Products Administration on September 19, 2024[12]